Short interest for RadNet gives investors a sense of the degree to which investors are betting on the decline of RadNet's stock. Short interest data is updated every two weeks.

RadNet Stock (NASDAQ:RDNT), Short Interest Report

RadNet

RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.

Long Ideas

News

Small Cap

Markets

Media

Trading Ideas

DDOG

LNTH

MRVL

ONON

RDNT

SOFI

On CNBC’s &#34;Mad Money Lightning Round,&#34; Jim Cramer said  Marvell Technology, Inc. (NASDAQ: MRVL) reported a mixed quarter.

Cramer Calls Datadog &#39;Dynamite,&#39; Puts SoFi In Dog House: &#39;What The Heck Is Going On&#39;

Penny Stocks

Intraday Update

Movers

ADAP

AEVA

AIMD

AIRE

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AQST

ASLE

BBAI

BREA

CERO

COOK

COST

CRML

CRMT

CTOS

DOGZ

DOMO

EGOX

GIFI

GRFS

GROM

IMRN

JYNT

MIRA

MOBX

PRCH

PRTS

RDFN

REFR

RWAY

SWBI

SWVL

VIRX

WLDN

Shares of  Marvell Technology, Inc. (NASDAQ: MRVL) fell sharply during Friday’s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Pre-Market Outlook

U.S. stock futures were mixed this morning, with the Dow futures falling by around 30 points on Friday.

AerSale Posts Downbeat Results, Joins Costco, MongoDB And Other Big Stocks Moving Lower In Friday&#39;s Pre-Market Session

RadNet Inc

Loop Media, Inc. ("Loop Media") (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPTV#NYSE">LPTV</a>), a leading multichannel streaming CTV platform that provides curated music videos, sports highlights, news, premium entertainment channels and digital signage for businesses, and RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), a national leader in providing high-quality, cost-effective outpatient diagnostic imaging services, today announced that Loop Media has been selected by RadNet to power RadNet's RadNetTV Channel throughout its network of 366 imaging centers.
Loop Media's ad sales services and technology stack were selected by RadNet, who was searching for a reliable and consistent technology partner with capability to deliver programmatic ad sales, personalized RadNet branded channels, and customized signage, as well as provide a robust platform for RadNet's own content to be streamed across the RadNetTV imaging network venues. RadNetTV is a network of TVs in RadNet's imaging locations in seven states, which broadcasts original, entertaining and educational programming to its patients and guests, with an estimated viewership of over ten-million each year.
"Our selection of Loop&#xAE; provides the logical next step for RadNetTV," said Paul Colacchio, Vice President of Communications and PR at RadNet. "We are able to leverage Loop Media's technology, experience and people to monetize our TV network and further define and promote our brand with a highly personalized entertainment offering."
"Our relationship with RadNet demonstrates Loop's commitment to partnering with companies seeking to extract the most value from their entertainment content streamed to their existing network of venues," said Jon Niermann, Founder, Loop Media, Inc. "Loop Media is able to effectively and efficiently curate entertainment channels for our Partner Platform clients geared towards a company's patients, customers, staff, and others, in a very cost-effective way and use our ad tech stack to deliver programmatic ad demand to those channels."
To learn more about how Loop&#xAE; can optimize your business, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.loop.tv&amp;esheet=53959116&amp;newsitemid=20240429402843&amp;lan=en-US&amp;anchor=http%3A%2F%2Fwww.loop.tv&amp;index=1&amp;md5=18ed75e4747b015e25a114b7a163c984">http://www.loop.tv</a>

LPTV

Loop Media Selected By RadNet To Provide Ad Sales Services, Branded Channels, And Customized Signage Across RadNetTV

As an iconic figure in women&#39;s basketball, Sheryl Swoopes enjoyed an illustrious career, earning three Olympic gold medals and three Most Valuable Player awards in the WNBA, cementing her status as one of the greatest players of all time. Inducted into the Basketball Hall of Fame in 2017, Swoopes continues to inspire generations with her remarkable achievements, both on and off the court.
Swoopes has a personal connection to cancer and specifically breast cancer, having lost both of her aunts to the disease. RadNet and Swoopes will together support a movement towards greater health equity and collaborate on efforts to combat healthcare disparities. Swoopes&#39; influence and advocacy can spark meaningful change in how communities approach preventive healthcare and population health screening.
&quot;Growing up, Walmart was more than just a store to me&mdash;it was a part of my family&#39;s routine. My mom and aunts would take me along as they shopped. Looking back, I cannot help but think how different things might have been if screening services like RadNet&#39;s MammogramNow had been available,&quot; said Swoopes. &quot;I lost two aunts to breast cancer. That personal connection fuels my passion for this collaboration. Even having that personal experience with cancer, I did not realize how little I knew about the importance of annual screenings. My basketball career has provided me with a platform to influence millions of people, and having seen firsthand the devastation cancer can bring, I am driven to ensure that others have access to early detection and life-saving preventive care.&quot;

RadNet Says It Teamed Up With Basketball Icon Sheryl Swoopes To Promote Healthcare Equity And Access

Health Care

General

RadNet Prices And Upsizes Its Previously Announced Term Loan And Revolving Credit Facility Refinancing Transaction

This acquisition, which is anticipated to be completed before the end of the&nbsp;second quarter&nbsp;of 2024, is RadNet&#39;s second announced transaction in Houston, and upon closing, will bring the number of RadNet centers in this geography to 13.&nbsp;The six multimodality centers to be acquired offer a broad range of imaging services, including MRI, CT, mammography, ultrasound and x-ray, and currently operate under the American Health Imaging brand. Shortly after the completion of the acquisition, we intend to transition the branding of these centers to Houston Medical Imaging. RadNet anticipates that the acquired centers will add over 100,000 procedures and&nbsp;$15 million&nbsp;of revenue on an annual basis.

RadNet Signs Definitive Deal To Purchase Assets Of Six Imaging Centers In The Greater Houston, Texas Metropolitan Area; No Terms Disclosed

At December 31, 2023, the debt facilities that RadNet intends to refinance included a&nbsp;$679 million&nbsp;term loan balance due April of 2028 and an undrawn&nbsp;$195 million&nbsp;revolving credit facility maturing April of 2026. RadNet is seeking to replace these facilities with a proposed&nbsp;$840 million&nbsp;term loan with a maturity of seven years and&nbsp;$250 million&nbsp;revolving credit facility with a five year term. In addition to repaying the existing term loan, RadNet expects to use the proceeds from any refinancing transaction to pay fees and expenses of the transaction and to fund an additional approximately&nbsp;$148 million&nbsp;of cash to its balance sheet for growth opportunities and general corporate purposes.

RadNet Announced A Proposed Refinancing Transaction For Its Existing Term Loan And Revolving Credit Facility

Contracts

RadNet Established A New Joint Venture, Tri Valley Imaging Group, In March With Providence Health System, RadNet Contributed Four California Imaging Centers, Providence Contributed Three Imaging Centers

In the latest quarter, 4 analysts provided ratings for RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), showcasing a mix of bullish and bearish perspectives.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $53.0, a high estimate of $58.00, and a low estimate of $48.00. This current average reflects an increase of 13.56% from the previous average price target of $46.67. 
<img src="https://www.benzinga.com/files/images/story/2024/1711648809_0_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
A clear picture of RadNet's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Brian Tanquilut</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$58.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Andrew Mok</td>
<td>Barclays</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$48.00</td>
<td>-</td>
</tr>
<tr>
<td>David Macdonald</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RadNet. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RadNet compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for RadNet's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of RadNet's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/RDNT/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on RadNet analyst ratings.</a>
<h2>Unveiling the Story Behind RadNet</h2>
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments; The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures, and Artificial Intelligence segment develops and deploys clinical applications to enhance interpretation of medical images and improve patient outcomes with an emphasis on brain, breast, prostate, and pulmonary diagnostics. The company derives a majority of its revenue from the Imaging center segment.
<h3>RadNet's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: RadNet displayed positive results in 3 months. As of 31 December, 2023, the company achieved a solid revenue growth rate of approximately 9.51%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -0.44%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): RadNet's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of -0.3%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): RadNet's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of -0.07%, the company showcases efficient use of assets and strong financial health.
Debt Management: RadNet's debt-to-equity ratio surpasses industry norms, standing at 2.36. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>Analyst Ratings: What Are They?</h2>
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 4 Analyst Ratings Have To Say About RadNet

Truist Securities analyst David Macdonald reiterates RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $51 to $55.

Price Target

Reiteration

Truist Securities Reiterates Buy on RadNet, Raises Price Target to $55

On CNBC&rsquo;s &quot;Mad Money Lightning Round,&quot; Jim Cramer said Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) reported a mixed quarter. &quot;<a href="https://www.benzinga.com/news/24/03/37756021/marvells-latest-tech-leap-with-tsmc-a-2nm-chip-platform-set-to-transform-ai-infrastructure">We got to wait,&quot; he added. </a>
Last week, Marvell Technology unveiled a significant development in semiconductor technology through an expanded partnership with Taiwan Semiconductor Manufacturing Co (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tsm#NYSE">TSM</a>), launching the first-ever 2nm silicon intellectual property (IP) technology platform.
Cramer recommended buying Datadog, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddog#NASDAQ">DDOG</a>), saying that it is a &quot;dynamite&quot; company. &quot;It is expensive, but they really know what they&rsquo;re doing,&quot; he noted.
On Feb. 13, Datadog posted upbeat sales for its fourth quarter, but issued FY24 EPS guidance below estimates. The company clocked fourth-quarter FY23 revenue growth of 26% year-on-year to $589.649 million, beating the consensus of $568.695 million.
When asked about Centrus Energy Corp. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/leu#NYSE">LEU</a>), he said, &quot;Very speculative situation. I want you to buy the GE spinoff that&rsquo;s coming, it&rsquo;s Vernova. That has got nuke, and I love the balance sheet, and I love what the company&rsquo;s doing, and you want to be a little diversified.&quot;
On Feb. 8, Centrus Energy reported better-than-expected fourth-quarter financial results.
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a> 
Altimmune, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/alt#NASDAQ">ALT</a>) is an &quot;absolute, without a doubt, high-risk stock, when you could have Eli Lilly (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/lly#NYSE">LLY</a>),&quot; Cramer said.
Last month, Kerrisdale Capital announced a short position in the stock, claiming the company had little chance of competing against others in the GLP-1 space and calling it an &ldquo;<a href="https://www.benzinga.com/24/02/37102984/altimmune-stock-sinks-as-kerrisdale-capital-announces-short-position-obvious-dead-end">obvious dead end</a>.&rdquo;
When asked about Lantheus Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lnth#NASDAQ">LNTH</a>), he said, &quot;I&rsquo;ve been preferring RadNet (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>), because I think they&rsquo;ve got a better business model.&quot;
On March 4, Lantheus announced the FDA approval of DEFINITY for pediatric patients.
&quot;They were doing great, and then they did this convertible bond, and it just wrecked the stock,&quot; the &quot;Mad Money&quot; host said about SoFi Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sofi#NASDAQ">SOFI</a>). &quot;The stock has just been in the dog house ever since, and I don&rsquo;t like it when I tell people to buy a stock and it&rsquo;s staying in the dog house. We got to find out what the heck is going on there.&quot;
On March 5, SoFi Technologies announced a proposed $750 million convertible senior notes offering due 2029.
Cramer said On Holding AG (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/onon#NYSE">ONON</a>) had a &quot;controversial&quot; quarter. &quot;I am on the fence on On,&quot; he added.
<h3>Price Action</h3>
<ul>
<li>Shares of Marvell Technology gained 0.5% to close at $67.20 on Monday.</li>
<li>Datadog shares gained 0.4% to close at $120.87 on Monday.</li>
<li>Centrus Energy shares gained 1.4% to settle at $38.77.</li>
<li>Altimmune shares dipped 7.9% to settle at $9.08 on Monday.</li>
<li>Lantheus shares fell 2.8% to close at $56.52 on Monday.</li>
<li>Shares of SoFi rose 0.7% to settle at $7.08.</li>
<li>On Holding shares fell 0.4% to close at $33.10 on Monday.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37780512/traeger-and-3-other-stocks-under-5-insiders-are-buying"> Traeger And 3 Other Stocks Under $5 Insiders Are Buying</a>
Image: Shutterstock

Cramer Calls Datadog 'Dynamite,' Puts SoFi In Dog House: 'What The Heck Is Going On'

Shares of Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) fell sharply during Friday&rsquo;s session after the company reported fourth-quarter financial results and issued weak Q1 guidance.
Marvell said fourth-quarter revenue increased 1% year-over-year to $1.427 billion, which beat the consensus estimate of $1.42 billion. The chip designer reported quarterly earnings of 46 cents per share, which was in line with analyst estimates.
Marvell sees first-quarter revenue of $1.15 billion, plus or minus 5%, versus estimates of $1.371 billion. The company sees first-quarter adjusted earnings of 23 cents per share, plus or minus 5 cents per share, versus estimates of 40 cents per share. The company authorized a $3 billion buyback.
Marvell Technology shares dipped 9.6% to $76.91 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
Ainos, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aimd#NASDAQ">AIMD</a>) jumped 140% to $2.6899 after dipping 18% on Thursday.
Psyence Biomedical Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pbm#NASDAQ">PBM</a>) shares climbed 139% to $3.0350. Psyence Biomedical recently announced its subsidiary, Psyence Australia, received Human Research Ethics Committee approval to initiate its Phase IIb study.
Safe and Green Development Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sgd#NASDAQ">SGD</a>) shares jumped 138% to $1.57 after the company announced financing for the Norman Berry Expansion in Atlanta, Georgia.
MIRA Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mira#NASDAQ">MIRA</a>) shares climbed 48.5% to $1.36. MIRA Pharmaceuticals, last month, announced a research collaboration with Pharmaseed to research and evaluate Ketamir for patients with major depressive disorder and post-traumatic stress disorder.
CERo Therapeutics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cero#NASDAQ">CERO</a>) shares climbed 35.4% to $4.17 after surging over 20% on Thursday. CERo Therapeutics recently announced the publication of preclinical research analyzing CER-1236 in targeting Acute Myelogenous Leukemia tumor cells from human patients.
Willdan Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wldn#NASDAQ">WLDN</a>) gained 30.4% to $25.89 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance above estimates. Also, the company secured a contract worth approximately $30 million to $50 million over three years.
The Joint Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jynt#NASDAQ">JYNT</a>) gained 29% to $11.80 following fourth-quarter results.
Smith &amp; Wesson Brands, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swbi#NASDAQ">SWBI</a>) jumped 25.8% to $16.91 after the company reported better-than-expected third-quarter financial results.
Research Frontiers Incorporated (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/refr#NASDAQ">REFR</a>) climbed 25.6% to $1.42 following fourth-quarter results.
Gulf Island Fabrication, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gifi#NASDAQ">GIFI</a>) shares gained 24.1% to $6.43 after the company reported a year-over-year increase in fourth-quarter revenue results.
Grifols, S.A. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grfs#NASDAQ">GRFS</a>) gained 22.7% to $6.89 after the company announced it published its consolidated annual accounts for 2023.
DoubleDown Interactive Co., Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ddi#NASDAQ">DDI</a>) gained 21.6% to $14.25.
Dogness (International) Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dogz#NASDAQ">DOGZ</a>) gained 18.6% to $7.98.
Kidpik Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pik#NASDAQ">PIK</a>) gained 18.3% to $3.0177.
America&#39;s Car-Mart, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crmt#NASDAQ">CRMT</a>) jumped 16.5% to $72.56 following third-quarter results.
Porch Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prch#NASDAQ">PRCH</a>) rose 16.1% to $3.6099 after the company reported better-than-expected fourth-quarter financial results and issued FY24 guidance.
Samsara Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/iot#NYSE">IOT</a>) gained 14.3% to $39.28 after the company reported better-than-expected fourth-quarter financial results and issued FY25 guidance above estimates.
Viracta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/virx#NASDAQ">VIRX</a>) shares gained 13.5% to $0.9200 following fourth-quarter results.
Aeva Technologies, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aeva#NASDAQ">AEVA</a>) rose 12.6% to $1.34.
Adaptimmune Therapeutics plc (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adap#NASDAQ">ADAP</a>) gained 12.1% to $1.95. Adaptimmune Therapeutics recently reported better-than-expected quarterly EPS results.
HCI Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hci#NYSE">HCI</a>) gained 11.3% to $110.42 after the company reported better-than-expected fourth-quarter financial results.
NuScale Power Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/smr#NYSE">SMR</a>) jumped 10.5% to $4.9289.
Redfin Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdfn#NASDAQ">RDFN</a>) jumped 9.6% to $7.10.
reAlpha Tech Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aire#NASDAQ">AIRE</a>) rose 8.8% to $1.3599. reAlpha Tech, last month, appointed Michael Frenz as CFO and Mike Logozzo as President and COO.
Carnival Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ccl#NYSE">CCL</a>) gained 5% to $16.44.
<h3>Losers</h3>
Amylyx Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amlx#NASDAQ">AMLX</a>) shares fell 80.7% to $3.6596 after the company announced its PHOENIX phase 3 trial of AMX0035 for amyotrophic lateral sclerosis did not meet its primary endpoint and there was no statistical significance seen in secondary endpoints.
BigBear.ai Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NYSE">BBAI</a>) fell 30.8% to $2.6006 after the company reported worse-than-expected fourth-quarter financial results.
Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) tumbled 28.6% to $0.0819.
Critical Metals Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crml#NASDAQ">CRML</a>) fell 27.7% to $7.95.
Swvl Holdings Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swvl#NASDAQ">SWVL</a>) fell 26.3% to $5.45.
Immuron Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/imrn#NASDAQ">IMRN</a>) shares dipped 24.7% to $3.4250 after jumping 161% on Thursday.
AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) fell 24.4% to $7.11 after the company reported worse-than-expected fourth-quarter financial results.
CarParts.com, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/prts#NASDAQ">PRTS</a>) fell 24.3% to $1.8999 following fourth-quarter results.
Mobix Labs, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mobx#NASDAQ">MOBX</a>) fell 20.1% to $1.39.
Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) fell 19% to $0.8001 after surging 28% on Thursday. Nxu recently announced it successfully charged a Tesla Cybertruck.
Brera Holdings PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/brea#NASDAQ">BREA</a>) shares fell 16.9% to $1.62. Brera Holdings shares jumped 91% on Thursday after the company announced that its Executive Chairman, Daniel McClory, acquired a majority stake in the company. 
Custom Truck One Source, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ctos#NYSE">CTOS</a>) dipped 15.3% to $5.26 after the company reported mixed quarterly financial results.
Nexalin Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxl#NASDAQ">NXL</a>) fell 15.1% to $0.4627. Nexalin Technology recently announced results of a clinical study of its Gen-2 tACS device for the treatment of chronic insomnia.
Runway Growth Finance Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rway#NASDAQ">RWAY</a>) fell 13.5% to $11.68 following downbeat quarterly results.
Domo, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/domo#NASDAQ">DOMO</a>) fell 12.7% to $9.92 after the company issued soft first-quarter and FY25 guidance.
MediaAlpha, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/max#NYSE">MAX</a>) declined 12.4% to $19.05 after the company announced a secondary offering of 3 million shares.
Genesco Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gco#NYSE">GCO</a>) fell 11.7% to $25.84 after the company&#39;s reported a fourth-quarter EPS miss and issued weak FY25 guidance.
Delek Logistics Partners, LP (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dkl#NYSE">DKL</a>) fell 11.3% to $39.51 after the company priced a public offering of 3,116,884 common units at $38.50 per unit.
Grom Social Enterprises, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grom#NASDAQ">GROM</a>) fell 11% to $1.13 after jumping 65% on Thursday. The company announced that it entered into a non-binding letter of intent to acquire Arctic7.
Traeger, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/cook#NYSE">COOK</a>) fell 10.5% to $2.11 after the company reported worse-than-expected fourth-quarter adjusted EPS results and issued FY24 revenue guidance below estimates.
Aquestive Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aqst#NASDAQ">AQST</a>) dipped 10% to $5.11 following fourth-quarter results.
Petr&oacute;leo Brasileiro S.A. - Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) shares fell 9.6% to $15.10 as the company reported a 6.3% year-over-year decline in its fourth-quarter net recurring profit.
Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) fell 7.5% to $727.08 following mixed second-quarter results.
MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) declined 6.4% to $385.82 after the company issued weak FY25 guidance.
Icahn Enterprises L.P. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/iep#NASDAQ">IEP</a>) fell 4.7% to $17.85.
RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) dipped 4.1% to $46.54. RadNet priced its public offering of 4.55 million common stock at $44 per share.
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37553898/cramer-says-sprout-social-is-in-a-hot-spot-but-this-energy-stock-is-too-down-and-out"> Cramer Says Sprout Social Is In A &#39;Hot Spot,&#39; But This Energy Stock Is &#39;Too Down And Out&#39; </a>

Why Marvell Technology Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

WIIM

RadNet shares are trading lower after the company priced a 4.55 million share common stock offering at $44 per share.

U.S. stock futures were mixed this morning, with the Dow futures falling by around 30 points on Friday.
Shares of AerSale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asle#NASDAQ">ASLE</a>) fell sharply in today&rsquo;s pre-market trading after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/ASLE/earnings">fourth-quarter financial results</a>.
AerSale posted adjusted loss of 2 cents per share, versus market estimates for a profit of 45 cents per share. The company&rsquo;s quarterly sales came in at $94.422 million, missing expectations of $156.368 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
AerSale shares tumbled 19.4% to $7.58 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>BigBear.ai Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bbai#NASDAQ">BBAI</a>) declined 17.6% to $3.10 in pre-market trading after the company reported worse-than-expected fourth-quarter financial results.</li>
<li>Petr&oacute;leo Brasileiro S.A. - Petrobras (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/pbr#NYSE">PBR</a>) shares dipped 11.4% to $14.80 in pre-market trading as the company reported a 6.3% year-over-year decline in its fourth-quarter net recurring profit.</li>
<li>MongoDB, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mdb#NASDAQ">MDB</a>) fell 8.1% to $378.65 in pre-market trading after the company issued weak FY25 guidance.</li>
<li>RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) dipped 6.8% to $45.20 in pre-market trading. RadNet priced its public offering of 4.55 million common stock at $44 per share.</li>
<li>Runway Growth Finance Corp. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rway#NASDAQ">RWAY</a>) fell 6.5% to $12.62 in pre-market trading following downbeat quarterly results.</li>
<li>Marvell Technology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrvl#NASDAQ">MRVL</a>) fell 6% to $80.03 in pre-market trading after the company reported fourth-quarter financial results and issued weak Q1 guidance. The company authorized a $3 billion buyback.</li>
<li>Costco Wholesale Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cost#NASDAQ">COST</a>) fell 5% to $746.03 in pre-market trading following mixed second-quarter results.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37553303/investor-sentiment-improves-further-s-p-500-surges-to-fresh-high"> Investor Sentiment Improves Further, S&amp;P 500 Surges To Fresh High</a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

AerSale Posts Downbeat Results, Joins Costco, MongoDB And Other Big Stocks Moving Lower In Friday's Pre-Market Session

RadNet, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, announced today the pricing of its underwritten public offering of 4,550,000 shares of its common stock at a price to the public of $44.00 per share. The gross proceeds to RadNet from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be approximately $200 million.

Reported Earlier, RadNet Prices Public Offering Of 4.55M Common Stock At $44/Share

RadNet shares are trading lower after the company announced a $200 million underwritten public offering of common stock.

In addition, RadNet intends to grant the underwriters a&nbsp;30-day&nbsp;option to purchase up to an additional&nbsp;$30 million of shares of common stock.&nbsp;RadNet intends to use the net proceeds from the proposed offering for general corporate purposes and potential future acquisitions.

Offerings

RadNet Plans Proposed $200M Public Offering Of Common Stock

Barclays analyst Andrew Mok initiates coverage on RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Equal-Weight rating and announces Price Target of $48.

Initiation

Barclays Initiates Coverage On RadNet with Equal-Weight Rating, Announces Price Target of $48

RadNet shares are trading higher after Truist Securities maintained a Buy rating on the stock and raised its price target from $42 to $51.

Truist Securities analyst David Macdonald maintains RadNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RDNT#NASDAQ">RDNT</a>) with a Buy and raises the price target from $42 to $51.

Truist Securities Maintains Buy on RadNet, Raises Price Target to $51

Shares of Zscaler, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/zs#NASDAQ">ZS</a>) shares fell sharply during Friday&rsquo;s session following second-quarter results.
Zscaler posted better-than-expected earnings and sales results for its second quarter on Thursday. The company said it expects fiscal year 2024 non-GAAP income from operations between $395 million and $400 million and net income per share between $2.73 and $2.77.
Zscaler shares fell 10.1% to $217.43 on Friday.
Here are some other stocks moving in today&#39;s mid-day session.
<h3>Gainers</h3>
<ul>
<li>BioVie Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bivi#NASDAQ">BIVI</a>) shares climbed 96.1% to $2.4319. BioVie&#39;s Ne3107 demonstrated potential improvements in motor and non-motor symptoms for Parkinson&#39;s disease patients and may be realigning physiological processes for Alzheimer&#39;s patients.</li>
<li>Adial Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/adil#NASDAQ">ADIL</a>) gained 68.4% to $3.4350. Adial Pharmaceuticals was awarded a new patent covering AD04 for the potential treatment of opioid use disorder.</li>
<li>Cardiff Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/crdf#NASDAQ">CRDF</a>) shares rose 41.5% to $2.50 after the company reported better-than-expected fourth-quarter financial results, provided a clinical update on the Phase 2 randomized second-line ONSEMBLE trial in patients with RAS-mutated mCRC and announced the first patient was dosed in the randomized first-line RAS-mutated mCRC trial.</li>
<li>Minim, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/minm#NASDAQ">MINM</a>) shares rose 41.4% to $6.09. On Feb. 20, Minim entered into an employment agreement with David Lazar to engage him as CEO, CFO, following resignation of Jeremy Hitchcock.</li>
<li>The RealReal, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/real#NASDAQ">REAL</a>) gained 39.1% to $2.4613 following upbeat quarterly results.</li>
<li>Nxu, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nxu#NASDAQ">NXU</a>) shares gained 36.4% to $1.09 after the company announced it successfully charged a Tesla Cybertruck on Feb. 26.</li>
<li>Jaguar Health, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jagx#NASDAQ">JAGX</a>) climbed 35.3% to $0.0798.</li>
<li>Dell Technologies Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dell#NYSE">DELL</a>) rose 26.3% to $119.52 as the company reported better-than-expected fourth-quarter financial results and increased its annual cash dividend by 20%.</li>
<li>Sweetgreen, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/sg#NYSE">SG</a>) gained 26% to $16.05 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) climbed 25% to $1.61.</li>
<li>Everbridge, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/evbg#NASDAQ">EVBG</a>) rose 24.5% to $35.19 after it amended and restated the previously announced merger agreement with Thoma Bravo.</li>
<li>NetApp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ntap#NASDAQ">NTAP</a>) shares gained 24.4% to $110.85 after the company reported better-than-expected third-quarter financial results and issued guidance.</li>
<li>Xponential Fitness, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/xpof#NYSE">XPOF</a>) climbed 24% to $12.50 following strong quarterly sales.</li>
<li>Myomo, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/myo#NYSE">MYO</a>) gained 21.9% to $3.73.</li>
<li>Ventyx Biosciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vtyx#NASDAQ">VTYX</a>) climbed 20.1% to $8.50.</li>
<li>MSP Recovery, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lifw#NASDAQ">LIFW</a>) gained 18.8% to $1.01.</li>
<li>Opera Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/opra#NASDAQ">OPRA</a>) rose 18.8% to $14.47 following strong sales.</li>
<li>REGENXBIO Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rgnx#NASDAQ">RGNX</a>) climbed 18.5% to $20.66.</li>
<li>RadNet, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rdnt#NASDAQ">RDNT</a>) gained 18.1% to $44.71 following strong quarterly results.</li>
<li>Sana Biotechnology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sana#NASDAQ">SANA</a>) rose 17.3% to $11.78 after the company reported a year-over-year increase in fourth-quarter financial results.</li>
<li>Tidewater Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tdw#NYSE">TDW</a>) gained 15.3% to $80.73 following fourth-quarter financial results.</li>
<li>Y-mAbs Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ymab#NASDAQ">YMAB</a>) gained 14.3% to $19.09 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Repay Holdings Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rpay#NASDAQ">RPAY</a>) rose 14.4% to $9.94 following upbeat quarterly results.</li>
<li>Root, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/root#NASDAQ">ROOT</a>) gained 14.2% to $36.66. Jefferies analyst Yaron Kinar upgraded Root from Hold to Buy and raised the price target from $10 to $40.</li>
<li>MasTec, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mtz#NYSE">MTZ</a>) rose 11.2% to $83.89 following strong quarterly results.</li>
<li>Rambus Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rmbs#NASDAQ">RMBS</a>) gained 9.3% to $64.76. Rambus initiated accelerated share repurchase program to repurchase an aggregate of $50 million of its common stock.</li>
<li>Arvinas, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/arvn#NASDAQ">ARVN</a>) rose 9.2% to $50.21. Barclays analyst Peter Lawson maintained Arvinas with an Overweight and raised the price target from $26 to $60.</li>
<li>The Cooper Companies, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/coo#NYSE">COO</a>) gained 7.4% to $100.61 after the company reported better-than-expected first-quarter financial results and raised guidance.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>GigCapital5, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gia#NASDAQ">GIA</a>) shares fell 60.7% to $4.35. GigCapital5 announced closing date of March 4, 2024 for business combination with QT Imaging.</li>
<li>Fisker Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fsr#NYSE">FSR</a>) shares tumbled 44.6% to $0.4035 after the company reported preliminary fourth-quarter total revenue results below estimates and said it expects to conclude there is substantial doubt about its ability to continue as a going concern when its annual financial statements are filed with the SEC.</li>
<li>Sidus Space, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sidu#NASDAQ">SIDU</a>) fell 39.9% to $5.41. Sidus Space priced public offering 1,321,000 Class A common share at $6 per share.</li>
<li>Scilex Holding Company (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sclx#NASDAQ">SCLX</a>) shares declined 39.7% to $1.37 after reporting a $10 million bought deal offering.</li>
<li>DermTech, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dmtk#NASDAQ">DMTK</a>) fell 32.8% to $0.86 after the company reported worse-than-expected quarterly revenue results.</li>
<li>Precision BioSciences, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dtil#NASDAQ">DTIL</a>) fell 31.7% to $12.62 after the company announced a $40 million offering of common stock and warrants.</li>
<li>Volcon, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vlcn#NASDAQ">VLCN</a>) fell 30.1% to $0.93.</li>
<li>Tritium DCFC Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dcfc#NASDAQ">DCFC</a>) fell 27.4% to $0.1031.</li>
<li>Vivani Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vani#NASDAQ">VANI</a>) declined 27% to $3.0798. Vivani Medical announced pricing of $15 million registered direct offering of common stock and warrants.</li>
<li>Humacyte, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/huma#NASDAQ">HUMA</a>) shares dipped 25.3% to $3.2450. Humacyte priced its $40.2 million public offering of 13.4 million common stock at $3 per share.</li>
<li>New York Community Bancorp, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nycb#NASDAQ">NYCB</a>) fell 24.2% to $3.6301 after the company identified material weakness in internal controls and announced a leadership transition.</li>
<li>JAKKS Pacific, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/jakk#NASDAQ">JAKK</a>) fell 23.7% to $26.79 following weak quarterly results.</li>
<li>TTEC Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttec#NASDAQ">TTEC</a>) dipped 22.6% to $13.50 after the company reported mixed fourth-quarter financial results and issued FY24 adjusted EPS and revenue guidance below estimates.</li>
<li>Gritstone bio, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grts#NASDAQ">GRTS</a>) fell 20.5% to $2.2250 after the company announced an approximately 40% reduction of its workforce.</li>
<li>NCR Voyix Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vyx#NYSE">VYX</a>) declined 19.8% to $11.72. NCR Voyix said it sees preliminary FY23 revenue of $3.830 billion.</li>
<li>Cue Health Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/hlth#NASDAQ">HLTH</a>) shares fell 15.6% to $0.2699. Cue Health has received a decision to grant European patent number EP3191849 titled &quot;Systems and Methods for Detection and Quantification of Analytes.&quot;</li>
<li>P10, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/px#NYSE">PX</a>) fell 15.2% to $7.86 following fourth-quarter results.</li>
<li>Elastic N.V. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/estc#NYSE">ESTC</a>) shares dipped 14.1% to $114.91 after the company reported third-quarter financial results.</li>
<li>American Coastal Insurance Corporation (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/acic#NASDAQ">ACIC</a>) fell 13.1% to $12.11 following weak sales.</li>
<li>B. Riley Financial, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/rily#NASDAQ">RILY</a>) shares declined 12.5% to $15.96 after the company reported fourth-quarter financial results and announced it has launched a review of strategic alternatives for its Appraisal and Valuation Services, and Retail, Wholesale &amp; Industrial Solutions businesses.</li>
<li>SoundHound AI, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/soun#NASDAQ">SOUN</a>) shares fell 11.6% to $6.56 after the company reported weaker-than-expected fourth-quarter financial results.</li>
<li>Senseonics Holdings, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sens#NASDAQ">SENS</a>) fell 10.1% to $0.6311 following fourth-quarter results.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) fell 9.7% to $1.3715 after the company reported worse-than-expected fourth-quarter financial results and issued FY24 revenue guidance below estimates.</li>
<li>Ginkgo Bioworks Holdings, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dna#NYSE">DNA</a>) fell 9.5% to $1.3750 following downbeat quarterly results.</li>
<li>Xcel Energy Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/xel#NASDAQ">XEL</a>) fell 6.4% to $49.29.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/03/37414137/jim-cramer-says-this-is-a-smart-consulting-company-calls-commercial-metals-company-a-win"> Jim Cramer Says This Is A &#39;Smart Consulting Company,&#39; Calls Commercial Metals Company A Winner</a>

ACIC

ADIL

ARVN

BIVI

CRDF

DCFC

DELL

DMTK

DTIL

ESTC

EVBG

GRTS

HLTH

HUMA

JAGX

JAKK

LIFW

MINM

NTAP

NYCB

OPRA

REAL

RGNX

RILY

RMBS

ROOT

RPAY

SANA

SCLX

SENS

SIDU

SOUN

TTEC

VANI

VLCN

VTYX

XPOF

YMAB

Why Zscaler Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session

RadNet shares are trading higher after the company reported better-than-expected Q4 financial results and raised Imaging Center segment total net revenue guidance.

RadNet, Inc. (RDNT) Q4 2023 Earnings Call Transcript

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Sotera Health (SHC – Research Report), Radnet (RDNT ...

Analysts Are Bullish on Top Healthcare Stocks: Sotera Health (SHC), Radnet (RDNT)

RadNet to offer $200M worth of shares in a public offering

RadNet announces pricing of public offering

Radnet Inc (RDNT) is near the top in its industry group according to InvestorsObserver. RDNT gets an overall rating of 59. That means it scores higher than 59 percent of stocks. Radnet Inc gets a 84 rank in the Diagnostics and Research industry. Diagnostics and Research is number 83 out of 148 industries. RDNT has an Overa

Radnet Inc (RDNT) has risen 3.99% in a Week, Should You Accumulate?

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Praxis Precision Medicines (PRAX – Research Report),...

Analysts' Top Healthcare Picks: Praxis Precision Medicines (PRAX), GlycoMimetics (GLYC)

RadNet proposes refinancing its term loan and revolving credit facility

ClearBridge Small Cap Growth Strategy Q2 2024 Portfolio Manager Commentary

RadNet to purchase assets of six imaging centers in Houston

RadNet prices and upsizes refinancing transactions

ALTM

ARLTF

CASY

CNMD

DUOL

FOXF

FWRD

GLYC

IART

INSM

INTA

IRDM

MEDP

MSTR

NVDA

OMCL

PRAX

SHLS

SMCI

TREX

VKTX

WING

XMTR

Financing

Press Releases

RadNet Announces Closing of Public Offering of Common Stock

RadNet Announces Outpatient Radiology Partnership with Providence Health System to Include Seven Centers in Burbank, Santa Clarita and the Northern San Fernando Valley of Los Angeles

RadNet Announces a Proposed Refinancing of its Term Loan and Revolving Credit Facility

RadNet to Make its Second Acquisition in Houston, Texas

RadNet Announces Pricing and Upsizing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction

RadNet Teams Up with Basketball Icon Sheryl Swoopes to Promote Healthcare Equity and Access

RadNet's Delaware Imaging Network Announces Ribbon-Cutting Ceremony for Mammography Service at Milford Walmart

RadNet Announces Closing of its Previously Announced Term Loan and Revolving Credit Facility Refinancing Transaction

RadNet, Inc. Announces Date of its First Quarter 2024 Financial Results Conference Call

Loop Media Selected by RadNet to Provide Ad Sales Services, Branded Channels, and Customized Signage Across RadNetTV

-

-

-

-

-

-

-

-

-

-

-

-

-

-

RadNet Stock (NASDAQ:RDNT), Short Interest Report

People Also Watch